Overview
The Tet Technology is the most widely used technology to control gene expression as documented by:
- More than 17,000 scientific publications as of 03/2018
- More than 1,500 accounts at Clontech alone, serving both academic and commercial customers
- Since 1996, more than 150 organisations have licensed the Tet Technology
- 17 out of the top 20 pharmaceutical companies based on their netsales in 2006 are currently licensees
IP Portfolio
- The TET IP Portfolio comprises 14 issued patents organised in 3 patent families
- The TET IP portfolio relates to the original and improved versions of transcriptional activators, silencers, responsive elements and chromosomal loci for transgenesis
- The Tet Technology is patent protected in North-America, Europe, Japan and Australia